Ignite Creation Date:
2024-05-06 @ 1:20 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03991403
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-04-03
First Post:
2019-06-05
Brief Title:
Study of Atezolizumab Combination Carboplatin Paclitaxel Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Study Overview
Official Title:
Study of Atezolizumab in Combination With Carboplatin Paclitaxel Bevacizumab vs With Pemetrexed Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR or ALK
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This randomized Phase III multicenter open-label study designed to evaluate the efficacy of Atezolizumab in combination with carboplatin paclitaxel bevacizumab compared with treatment with pemetrexed cisplatin in approximately 228 TKItyrosine kinase inhibitor pre treated patients with Stage IV non squamous non small cell lung cancer with activating EGFR mutation or ALK translocation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None